argenx SE (NASDAQ:ARGX) Shares Bought by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB lifted its position in shares of argenx SE (NASDAQ:ARGX) by 47.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,776 shares of the company’s stock after buying an additional 574 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in argenx were worth $1,092,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ARGX. Sanctuary Advisors LLC purchased a new position in argenx during the 2nd quarter valued at about $755,000. GAMMA Investing LLC increased its stake in shares of argenx by 47.5% during the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares in the last quarter. Ritholtz Wealth Management acquired a new position in shares of argenx during the 3rd quarter worth approximately $262,000. Creative Planning lifted its stake in argenx by 54.1% in the 3rd quarter. Creative Planning now owns 5,437 shares of the company’s stock valued at $2,947,000 after buying an additional 1,909 shares in the last quarter. Finally, Aaron Wealth Advisors LLC acquired a new stake in argenx during the 3rd quarter valued at $241,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on ARGX. Robert W. Baird downgraded argenx from an “outperform” rating to a “neutral” rating and upped their price objective for the company from $515.00 to $650.00 in a research report on Friday, November 1st. Piper Sandler raised their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 7th. Baird R W downgraded shares of argenx from a “strong-buy” rating to a “hold” rating in a report on Friday, November 1st. Truist Financial restated a “buy” rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Finally, Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and boosted their price target for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Trading Down 0.0 %

NASDAQ:ARGX opened at $646.45 on Tuesday. The firm’s fifty day simple moving average is $637.69 and its 200 day simple moving average is $578.86. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The firm has a market capitalization of $39.28 billion, a price-to-earnings ratio of -734.60 and a beta of 0.58.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.